How many investments has Longitude Capital made?

Longitude Capital has 92 tracked investments, 4 of which have exited via acquisition or IPO, including 4 dated in the last 24 months.

What stage does Longitude Capital invest at?

Longitude Capital invests at the Series A, Series B, Series C, Growth, Late Stage stages.

What is Longitude Capital's typical check size?

Longitude Capital typically writes checks of $10M – $30M.

What sectors does Longitude Capital focus on?

Longitude Capital focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.

Where is Longitude Capital located?

Longitude Capital is headquartered in Menlo Park, US.

Does Longitude Capital lead rounds?

Yes, Longitude Capital leads investment rounds.

Who does Longitude Capital co-invest with?

Longitude Capital most often shares deals with RA Capital, Frazier Life Sciences, New Enterprise Associates (NEA), among 179 tracked co-investors.

Longitude Capital

Growth equity

Menlo Park · Series A–Late Stage · 78 people tracked

Also known as LONGITUDE CAPITAL MANAGEMENT CO., LLC · Longitude Venture Partners

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

Invests in mid- to commercial-stage biotech and medtech with clinically de-risked assets, using spin-outs, recapitalizations, PIPEs and other structured transactions, and sources deals via its academic research network.

Invests inBiotech Digital Health Healthtech Longevity Medical Devices Menlo Park North America United States

Source: firm website, verified Aug 25, 2026.

Stage

Series A–Late Stage

Check

$10M – $30M

Menlo Park, CA, US

Leads rounds

Leads

Instruments

Equity

Founded

2006

Last 12 months

2 investments

AUM

$2.4B

Tracked investments

Team · 78 people

from the firm's website & curated & public directories

Bakker· Managing Director & Founder· Boston

Founder and Managing Director of Longitude Capital focused on medical technology and health solutions. Previously founded the life sciences practice at Pequot Ventures and held roles at Waste Management International, Banque Paribas, and PaineWebber.

Enright· Managing Director & Founder· Menlo Park

Founder and Managing Director focused on biotechnology and health solutions. Previously co-led the life sciences practice at Pequot Ventures and held senior operating roles at Valentis, Hoffmann-La Roche, and Novartis.

Galletti· Venture Partner & Founder· Menlo Park

Venture Partner and Founder focused on health solutions. Previously a Senior Vice President in Pequot Ventures' life sciences practice and worked at Amerindo, Vector Fund Management, and J.P. Morgan.

Mr. Enright· Managing Director & Founder· Menlo Park

Co-founder and Managing Director focused on biotechnology and health solutions. He previously co-led the life sciences practice at Pequot Ventures and held senior roles at Valentis, Hoffman-La Roche, and Novartis. He holds an MBA from Wharton and a BS from Stanford.

Mr. Galletti· Venture Partner & Founder· Menlo Park

Venture Partner and co-founder focused on health solutions. He previously worked at Pequot Ventures, Amerindo, Vector Fund Management, and J.P. Morgan. He holds an MBA from Kellogg and a BA from Princeton.

Ms. Bakker· Managing Director & Founder· Bostonin

Co-founder and Managing Director focused on medical technology and health solutions. She previously founded the life sciences practice at Pequot Ventures and held roles at Waste Management International, Banque Paribas, and PaineWebber. She holds an MPA from Harvard Kennedy School and a BSc from Cornell.

Juliet Bakker· Managing Director· Bostonin

Managing Director and Founder of Longitude Capital who previously founded the life sciences investment practice at Pequot Ventures. She serves on numerous medtech boards and holds an MPA from Harvard Kennedy School and a BSc from Cornell.

j•••@longitudecapital.comreveal

Marc Galletti· Venture Partner and Founder· Menlo Parkin

Venture Partner and Founder focused on health solutions who previously worked at Pequot Ventures' life sciences practice. He holds an MBA from Kellogg and a BA from Princeton.

m•••@longitudecapital.comreveal

Patrick Enright· Managing Director· Menlo Parkin

Managing Director and Founder who co-led the life sciences practice at Pequot Ventures and has extensive biotech operating experience. He holds an MBA from Wharton and a BS from Stanford.

p•••@longitudecapital.comreveal

Bikoff· Managing Director· Menlo Park

Managing Director focused on medical technology who joined in 2016. Previously held strategy, finance, and operating roles at Cardinal Health, most recently as Director of North America Marketing for Cordis, and began his career at Deloitte Consulting.

Dr. Liu· Managing Director· Menlo Park

Managing Director focused on biotechnology who joined in 2018 after serving as an Engagement Manager at McKinsey. He holds an MD from Stanford and a BS from Johns Hopkins.

Helms· Managing Director & Chief Financial Officer· Menlo Park

Managing Director and CFO responsible for financial reporting and firm-wide finance, tax, HR, IT, and administration. She joined in 2008 from Sierra Ventures and is a licensed (inactive) CPA.

Liu· Managing Director· Menlo Park

Managing Director focused on biotechnology who joined in 2018 from McKinsey & Company's pharmaceuticals and medical products practice. Holds an MD from Stanford.

Mr. Bikoff· Managing Director· Menlo Park

Managing Director focused on medical technology who joined in 2016 after strategy, finance, and operating roles at Cardinal Health. He holds a BSE in Biomedical Engineering from Duke.

Mr. Young· Managing Director· Menlo Park

Managing Director focused on biotechnology who joined in 2022 after serving as COO and CFO of GRAIL and CFO of Jazz Pharmaceuticals. He holds an MBA and BS in Economics from Wharton.

Ms. Helms· Managing Director & Chief Financial Officer· Menlo Parkin

Managing Director and CFO responsible for the firm's fund financial reporting and day-to-day finance, tax, HR, IT, and administration. She joined in 2008 from Sierra Ventures and is a licensed (inactive) CPA.

Young· Managing Director· Menlo Park

Managing Director focused on biotechnology who joined in 2022. Previously served as COO and CFO of GRAIL and as CFO of Jazz Pharmaceuticals, and spent nearly 20 years in investment banking.

Brian Liu· Managing Director· Menlo Parkin

Managing Director focused on biotechnology who joined in 2018 from McKinsey & Company. He holds an MD from Stanford and a BS from Johns Hopkins.

b•••@longitudecapital.comreveal

Carolyn Helms· Managing Director and Chief Financial Officer· Menlo Parkin

Managing Director and CFO responsible for finance, tax, HR, IT, and administration. She joined in 2008 from Sierra Ventures and is a licensed CPA (inactive).

c•••@longitudecapital.comreveal

Matthew Young· Managing Director· Menlo Parkin

Managing Director who joined in 2022 after serving as COO/CFO of GRAIL and CFO of Jazz Pharmaceuticals. He focuses on biotechnology and holds an MBA and BS from Wharton.

m•••@longitudecapital.comreveal

Maxwell Bikoff· Managing Director· Menlo Parkin

Managing Director who joined in 2016 after strategy, finance, and operating roles at Cardinal Health. He focuses on medical technology and holds a BSE in Biomedical Engineering from Duke.

m•••@longitudecapital.comreveal

Daisy Liech· Managing Director and Chief Financial Officer· Kenyain

Franz Wocheslander· Managing Director· Germanyin

w•••@bayernkapital.dereveal

Sean Smith· Managing Director· United Kingdomin

Shota Ozawa· Managing Director· Tokyo, Japanin

Dr. Shota Ozawa joined MPH in 2023 with a background in business development, alliance management, and research across molecular biology, oncology, neurology, and nephrology. He draws on pharmaceutical development experience from Mitsubishi Tanabe Pharma to support portfolio companies.

s•••@mp-healthcare.comreveal

Dr. Ely· Principal· Boston

Principal focused on biotechnology who joined full-time in 2022 after serving as a Longitude Research Fellow. He earned a PhD in Biology from MIT specializing in gene editing and cancer immunology.

Dr. Guo· Vice President· Menlo Park

Vice President focused on biotechnology who joined in 2025 after fellowships with Foresite Capital, Aditum Bio, and Insight Partners. He holds a PhD from Harvard Medical School, an MD from UCSF, and a BA from Cornell.

Ely· Principal· Boston

Principal focused on biotechnology who joined full-time in 2022 after serving as a Longitude Research Fellow. Holds a PhD in Biology from MIT specializing in gene editing and cancer immunology.

Guo· Vice President· Menlo Park

Vice President focused on biotechnology who joined in 2025 after fellowships with Foresite Capital, Aditum Bio, and Insight Partners. Holds a PhD from Harvard Medical School and an MD from UCSF.

Jimmy Guo· Vice President· Menlo Parkin

Vice President focused on biotechnology who joined in 2025 after fellowships at Foresite Capital, Aditum Bio, and Insight Partners. He holds a PhD from Harvard Medical School and an MD from UCSF.

Zack Ely· Principal· Boston

Principal focused on biotechnology who joined full-time in 2022 after being a Longitude Research Fellow. He earned a PhD in Biology from MIT.

Dr. Qi· Venture Partner· Menlo Park

Venture Partner focused on biotechnology who began working with the firm in 2025. He previously covered pharma and biotech at Seven Fleet Capital and Walleye Capital and worked at the FDA and Hatteras Venture Partners. He holds a PhD from UNC Chapel Hill.

Dr. Vanhove· Venture Partner· Menlo Park

Venture Partner focused on biotechnology with over 25 years of clinical drug development and medical affairs experience. She joined in 2023 after serving as CMO of Surrozen. She holds an MD and PhD in Pharmacology from the Catholic University of Leuven.

Qi· Venture Partner· Menlo Park

Venture Partner focused on biotechnology who began work with the firm in 2025. Previously a co-founding investment analyst at Seven Fleet Capital and an analyst at Walleye Capital, with prior roles at the FDA and Hatteras Venture Partners.

Tim Qi· Venture Partner· Menlo Park

Venture Partner focused on biotechnology who began working with the firm in 2025, previously an investment analyst at Seven Fleet Capital and Walleye Capital. He holds a PhD from UNC Chapel Hill.

Vanhove· Venture Partner· Menlo Park

Venture Partner focused on biotechnology with over 25 years of clinical drug development and medical affairs experience. Joined in 2023 after serving as CMO of Surrozen and holding senior roles at Jazz Pharmaceuticals, Depomed, and others.

James Heath· Venture Partner· Londonin

Trudy Vanhove· Venture Partner· Menlo Parkin

Venture Partner focused on biotechnology with over 25 years of clinical drug development experience, most recently CMO of Surrozen. She holds an MD and PhD from the Catholic University in Leuven.

Advani· Senior Associate· Menlo Park

Senior Associate focused on medical technology who joined in 2024. Previously an investment banking analyst at Cowen and a private equity analyst at Montage Partners.

Bethany Chen· Senior Associate· Bostonin

Senior Associate focused on biotechnology who joined in 2024 from Morgan Stanley's Healthcare group. She holds an MS in Biology and BS from Stanford.

Cabreros· Director of Operations & Facilities· Menlo Park

Director of Operations & Facilities and a member of the Finance team who joined in 2017. Previously a Tax Controller at Northgate Capital and held accounting roles at ONSET Ventures and PwC.

Caruso Wilson· Compliance and Legal Manager· Menlo Park

Compliance and Legal Manager who joined in 2022. Previously a compliance consultant at ACA Global advising SEC-registered investment advisers.

Chen· Senior Associate· Boston

Senior Associate focused on biotechnology who joined in 2024. Previously an investment banking analyst in Morgan Stanley's healthcare group covering biopharma.

Cristiana Oliveira· Head of Legal and Chief Compliance Officer· Menlo Parkin

Head of Legal and Chief Compliance Officer who joined in 2020 from Weil, Gotshal & Manges. She holds a JD and BA from UC Berkeley.

Denise Knopping· VP of People· Menlo Parkin

VP of People who joined in 2025 after leading Total Rewards and People Operations at GRAIL and Jazz Pharmaceuticals. She is a licensed CPA (inactive).

Dennis Gong· Senior Associate· Bostonin

Senior Associate focused on biotechnology who joined in 2026 after consulting for Longitude and fellowships at Compound and Divergence Labs. He earned a PhD from the MIT/Harvard HST program.

Dr. Gong· Senior Associate· Boston

Senior Associate focused on biotechnology who joined in 2026 after consulting for the firm and completing fellowships at Compound and Divergence Labs. He earned a PhD from the MIT/Harvard HST program.

Dr. Lim· Senior Analyst· Menlo Park

Senior Analyst focused on biotechnology public equities who joined in 2024, previously an analyst at Deep Track Capital, Lynx1, Walleye Capital, and Columbia Threadneedle. He holds a PhD in Neurobiology from Caltech.

Erin Wright· Executive Assistant· Bostonin

Executive Assistant who joined in 2018 after owning a Bar Method fitness studio and working in production at ABC News 20/20. She holds a BA from Fordham.

Gong· Senior Associate· Boston

Senior Associate focused on biotechnology who joined in 2026 after consulting for the firm and completing fellowships at Compound and Divergence Labs. Holds a PhD from the MIT/Harvard HST program.

Holman· Controller· Menlo Park

Controller who joined in 2013. Previously an audit associate at Moss Adams and PwC serving technology, life sciences, and venture capital clients.

Hughes· Executive Assistant· Menlo Park

Executive Assistant supporting the biotechnology and medical technology teams who joined in 2007. Previously an executive assistant at Pequot Ventures.

Jeff Jonson· Director of IT· Menlo Parkin

Director of IT who joined in 2023 from AllCovered and has over 15 years of managed IT and venture capital IT experience. He holds a BS from DeVry University.

Jonson· Director of IT· Menlo Park

Director of IT who joined in 2023. Previously held engineering roles at AllCovered and has over 15 years of experience managing IT operations at managed service providers and venture capital firms.

Karen Lok· Vice President of Finance· Menlo Parkin

Vice President of Finance who joined in 2015 after seven years at KPMG focused on life science venture capital funds. She holds a BA in Economics from UC Santa Barbara.

Knopping· VP of People· Menlo Park

VP of People who joined in 2025. Previously Head of Total Rewards and People Operations at GRAIL and Head of Total Rewards at Jazz Pharmaceuticals.

Lim· Senior Analyst· Menlo Park

Senior Analyst focused on public equities in biotechnology who joined in 2024. Previously an analyst at Deep Track Capital, Lynx1, Walleye Capital, and Columbia Threadneedle, and an investment banking VP at Jefferies.

Lok· Vice President of Finance· Menlo Park

Vice President of Finance who joined in 2015. Previously spent seven years at KPMG (formerly Rothstein Kass) in audit and assurance focused on life science venture capital funds.

Michelle Shin· Senior Tax Manager· Menlo Park

Senior Tax Manager and member of the Finance team who joined in 2024 from a16z. She holds an MS in Taxation from Golden Gate University.

Mr. Advani· Senior Associate· Menlo Park

Senior Associate focused on medical technology who joined in 2024, previously an investment banking analyst at Cowen and a private equity analyst at Montage Partners.

Ms. Chen· Senior Associate· Boston

Senior Associate focused on biotechnology who joined in 2024, previously an investment banking analyst in Morgan Stanley's Healthcare group. She holds MS and BS degrees from Stanford.

Neil Advani· Senior Associate· Menlo Park

Senior Associate focused on medical technology who joined in 2024 from Cowen, where he covered medtech as an investment banking analyst.

Nicole Hughes· Executive Assistant· Menlo Park

Executive Assistant supporting the Biotechnology and Medical Technology teams who joined in 2007 from Pequot Ventures. She holds a BA from Menlo College.

Oliveira· Head of Legal & Chief Compliance Officer· Menlo Park

Head of Legal and Chief Compliance Officer who joined in 2020. Previously a senior associate at Weil, Gotshal & Manges advising on M&A, securities compliance, and venture financings.

Rod Lim· Senior Analyst – Public Equities· Menlo Park

Senior Analyst focused on biotechnology public equities who joined in 2024 from Deep Track Capital and other funds. He holds a PhD in Neurobiology from Caltech.

Rose Caruso Wilson· Compliance and Legal Manager· Menlo Park

Compliance and Legal Manager who joined in 2022 from ACA Global. She holds a JD from the University of San Francisco and a BA from Marquette.

Shin· Senior Tax Manager· Menlo Park

Senior Tax Manager and member of the Finance team who joined in 2024. Previously a tax manager at a16z and held tax roles at GI Partners, Pattern Energy Group, and PwC.

Stephanie Holman· Controller· Menlo Park

Controller who joined in 2013 after audit roles at Moss Adams and PwC serving technology and life sciences companies. She holds a BS in Microbiology from San Jose State.

Teresa Cabreros· Director of Operations & Facilities· Menlo Park

Director of Operations & Facilities and member of the Finance team who joined in 2017 from Northgate Capital. She holds a BA in Economics from UC Santa Cruz.

Wright· Executive Assistant· Boston

Executive Assistant who joined in 2018. Previously owned a Bar Method fitness studio and worked in production at ABC News 20/20.

Cindy Wang· Vice President· West Hartford, Connecticut, United Statesin

c•••@longitudecapital.comreveal

Callum Gallacher· Head of Legal & Chief Compliance Officer· Glasgow, Scotland, United Kingdomin

Dennis Gong· Senior Associate· Cambridge, Massachusetts, United Statesin

A bioengineering graduate from Johns Hopkins pursuing an HST PhD at Harvard/MIT.

Irfan Hussain· Vice President· New Yorkin

Joined LSEG as CIO in January 2024, leading the technology team. Previously a Partner and Chief Operating & Strategy Officer for Engineering at Goldman Sachs.

Meera Atreya· Senior Associate· Greater London, England, United Kingdomin

VP focused on net zero strategy, sustainable bioresource supply and use, biomass carbon removal and storage (BiCRS), and biofuel. Holds a PhD.

Sarah Federman· Senior Associate· Louisville, Colorado, United Statesin

VP of Landscape Decarbonization focused on biodiversity, forest ecology and management, and climate-smart agriculture. Holds a PhD.

Irvin Akinseye· Associate· Menlo Park, California

Reinaldo Diaz

What they invest in

from 83 of 99 portfolio companies

Biotech ×55Healthtech ×54Medical Devices ×30Digital Health ×20Hardware ×7AI & Machine Learning ×5SaaS ×5Wellness & Fitness ×3

HQs:United States×56Canada×1Switzerland×1Ireland×1

Who they back

founder profiles across 30 portfolio companies

63%

solo founders

19 of 30 mapped founding teams

Founding team size:solo founder×192 founders×63 founders×34+ founders×2

Investments · 99 tracked

founders shown can be your intro path

By year:2026 · 2 2025 · 1 2024 · 5 2023 · 2 2021 · 2 2019 · 1 2018 · 1 2017 · 3 2015 · 1 2014 · 220 dated

Veradermicsveradermics.com inNYSE: MANE✓ verified

Veradermics is developing VDPHL01, an extended-release oral minoxidil tablet intended as a non-hormonal prescription treatment for pattern hair loss in women and men.

BiotechHealthtechWest Hartford, US

Reid Waldman(Chief Executive Officer and Board Member)inTim Durso(Chief Technical Officer)Dominic Carrano(Chief Financial Officer and Treasurer)Mark Neumann(Chief Commercial and Strategy Officer)John W. Childs(Director)Jane Grant-Kels(Director)

Co-investorsConnecticut Innovations OUP (Osage University Partners)SR One Capital Management

Ceribellceribell.com in 𝕏NASDAQ: CBLLMay 2021

Ceribell is a medical technology company that develops products for detecting and monitoring seizures, including EEG-based diagnostic systems.

AI & Machine LearningDigital HealthHealthtechMedical DevicesSunnyvale, US

Josef Parvizi(Director)Xingjuan Chao(Executive Officer, Director)Xingjuan (Jane) Chao(President, CEO, Co-Founder & Director)Scott Blumberg(Executive Officer)Joseph Taylor(Director)Raymond Woo(Executive Officer)

Board seatJuliet Tammenoms Bakker· per SEC Form D

Co-investorsRA Capital Red Tree Venture ShangBay Capital LLC

Aeonbiopharmaaeonbiopharma.com inNYSE: AEON

AEON Biopharma develops ABP-450 (prabotulinumtoxinA), a branded biosimilar to BOTOX®, targeting therapeutic indications for neuromuscular conditions.

BiotechHealthtech

BioAge Labsbioagelabs.com in 𝕏NASDAQ: BIOAFeb 2024

BIOAGE develops therapies targeting the molecular pathways that drive aging to increase healthspan and address age-related chronic diseases.

BiotechHealthtechLongevityRichmond, US

Kristen Fortney, PhD(Co-Founder, CEO)Eric Morgen, MD(Co-Founder, COO)Kristen Fortney(Executive Officer, Director)inEric Morgen(Director)Dov Goldstein(Executive Officer)

BoardPatrick Enright(Director)in

Co-investorsAndreessen Horowitz Elad Gil Felicis Ventures IA Seed Ventures OrbiMed Pear VC +4 more

Boston Scientificbostonscientific.com inNYSE: BSX

Boston Scientific supports external researcher-initiated studies through its Investigator Sponsored Research program, which funds independent investigations addressing disease understanding and treatment gaps of interest to the medical community.

HealthtechMedical Devices

Lance Batesin

Co-investorsAndera Partners Council Excelestar Ventures Good Growth Capital New Enterprise Associates (NEA)Norwest Venture Partners +3 more

CG Oncologycgoncology.com in 𝕏NASDAQ: CGON

CG Oncology is a clinical-stage biotechnology company developing bladder-sparing oncolytic immunotherapies for patients with bladder cancer.

BiotechHealthtech

Co-investorsDecheng Capital Foresite Capital Palm Drive Capital RA Capital TCG Crossover ACORN BIOVENTURES +2 more

Collegium Pharmaceuticalcollegiumpharma.com in 𝕏NASDAQ: COLL

Collegium Pharmaceutical is a biopharmaceutical company developing a portfolio of medications to treat serious medical conditions.

BiotechCanton, US

Michael Heffernan(Executive Officer, Director)Paul Brannelly(Executive Officer)

BoardEran Nadav(Director)John Freund(Director)Patrick Heron(Director)inDavid Hirsch(Director)

Co-investorsAPERTURE Venture Partners EcoR1 Capital Frazier Life Sciences

Corcept Therapeuticscorcept.com inNASDAQ: CORT

Corcept develops cortisol modulators — molecules that regulate cortisol activity at the glucocorticoid receptor — to treat serious diseases across endocrinology, oncology, metabolism, and neurology.

AI & Machine LearningBiotechHealthtechMedical Devices

Co-investorsMountain Group Capital

CytomX TherapeuticsNASDAQ: CTMX

Clinical-stage biotechnology company developing conditionally activated, masked biologics designed to be localized to the tumor microenvironment.

BiotechSouth San Francisco, US

Sean McCarthy(Executive Officer, Director)

BoardTim Shannon(Director)inElaine V. Jones(Director)Neil Exter(Director)inFrederick W. Gluck(Director)Hoyoung Huh(Director)

Co-investorsCanaan Partners Third Rock Ventures

KALA BIOkalarx.comNASDAQ: KALA

BiotechArlington, US

Justin Hanes(Director)Kevin Pojasek(Executive Officer)Darius Kharabi(Executive Officer)Todd Bazemore(Executive Officer)Mark Iwicki(Executive Officer, Director)Mary Reumuth(Executive Officer)

Co-investorsSR One Capital Management Ysios Capital Atlas Venture Lux Capital Third Rock Ventures

Kestra Medical Technologieskestramedical.com inNASDAQ: KMTS

Kestra Medical develops wearable defibrillator technology aimed at protecting patients at risk of sudden cardiac arrest through rapid defibrillation.

HardwareHealthtechMedical Devices

Co-investorsAndera Partners Bain Capital Life Sciences

MicroTranspondermicrotransponder.com in 𝕏NASDAQ: MOBI

Mobia Medical (formerly MicroTransponder) develops Vivistim Paired VNS Therapy, an FDA-approved treatment for stroke survivors with moderate to severe upper extremity impairment.

Digital HealthHealthtechMedical DevicesAustin, US

Richard John Foust(Executive Officer, Director)Frank McEachern(Executive Officer, Director)

BoardNelson Bunker Curnes(Executive Officer, Director)Thomas Jordan Curnes II(Executive Officer, Director)Casey Tansey(Director)Dana Mead(Director)

Co-investorsUT Horizon Fund US Venture Partners

Rxsightrxsight.com in 𝕏NASDAQ: RXST

RxSight develops the Light Adjustable Lens (LAL), an FDA-approved intraocular lens that surgeons can adjust after cataract surgery to fine-tune a patient's prescription once the eye has healed.

HealthtechMedical DevicesPasadena, US

Robert H. Grubbs(Director)Daniel M. Schwartz(Director)D. Verne Sharma(Executive Officer, Director)Richard Drinkward(Executive Officer)

BoardJavier Perez-Sala(Director)Jan Bonel(Director)

Co-investorsFlying L Partners Foresite Capital H.I.G. Capital H.I.G. HealthBridge Partners RA Capital Visionary Ventures +1 more

Vaxcytevaxcyte.comNASDAQ: PCVX

Vaxcyte develops broad-spectrum vaccines to prevent bacterial infections, using a cell-free protein synthesis platform and synthetic chemistry techniques.

BiotechHealthtech

Grant Pickering(Founder)in

Co-investorsBioRock Ventures CTI Life Sciences Fund L.P.Foresite Capital Frazier Life Sciences RA Capital

Zenas Biopharmazenasbio.com inNASDAQ: ZBIO

Zenas BioPharma is a biopharmaceutical company developing therapies for autoimmune diseases, with two late-stage drug candidates: obexelimab, a bifunctional monoclonal antibody targeting CD19 and FcγRIIb to suppress B cell activity, and orelabrutinib, an oral BTK inhibitor.

BiotechHealthtechWaltham, US

LEON O. MOULDER, JR.(Director)Lonnie Moulder(Founder, CEO & Chairman)JOSEPH FARMER(Executive Officer)HUA MU(Executive Officer, Director)

BoardPATRICK GERALD ENRIGHT(Director)inHONGBO LU(Director)

Co-investorsDelos Capital New Enterprise Associates (NEA)Norwest Venture Partners Quan Capital SR One Capital Management Vivo Capital +1 more

Curasencurasen.com✓ verified

CuraSen Therapeutics is a privately funded biopharmaceutical company developing treatments that selectively activate adrenergic receptors in the brain to restore noradrenergic signaling.

BiotechHealthtech

Anthony Fordin

Co-investorsAlta Partners abrdn plc Intermediate Capital Group Johnson & Johnson Innovation – JJDC New Leaf Venture Partners Pappas Capital +2 more

Sydnexissydnexis.com in✓ verified

Sydnexis is a privately held biopharmaceutical company developing SYD-101, a proprietary low-dose atropine formulation in Phase 3 clinical trials to slow the progression of pediatric progressive myopia.

BiotechDigital HealthDel Mar, US

Patrick Johnson(Executive Officer, Promoter)Mary Jaqueline Johnson(Executive Officer)Mary Jacqueline Johnson(Executive Officer)Kevin Johnson(Director)Greg Ostrow(Executive Officer, Director)Kenneth Widder(Executive Officer, Director)

Co-investorsRA Capital Visionary Ventures

AlphaeonJan 2015SEC filingmedium confidence

HealthtechIrvine, US

Robert E. Grant(Executive Officer, Director)Jeevan Gore(Executive Officer)Robert Rhatigan(Executive Officer)Craig Kussman(Executive Officer)

BoardWilliam Link(Chairman of the Board)Robert Hayman(Director)

Board seatJuliet Bakker· per SEC Form D · $40.5M raise · filed Jan 2015

Axonics Modulation TechnologiesApr 2017SEC filingmedium confidence

Irvine, US

Michael Williamson(Executive Officer)Dan L. Dearen(Executive Officer)Michael V. Williamson(Executive Officer)Raymond W. Cohen(Executive Officer, Director)

BoardDarren Cai(Director)Raphael Wisniewski(Director)

Board seatJuliet Bakker· per SEC Form D · $55.1M raise · filed Apr 2018

Venus Conceptvenusconcept.com in 𝕏Nov 2019

Venus develops non-invasive, energy-based medical aesthetic devices for body, face, skin, and hair treatments, integrating robotics, AI, and IoT technologies.

BiotechHardwareHealthtechMedical DevicesToronto, US

Domenic Serafino(Executive Officer, Director)Kirk Gunhus(Executive Officer)Ross Portaro(Executive Officer)Anna Georgiadis(Executive Officer)Melissa Kang(Executive Officer)Michael Mandarello(Executive Officer)

Board seatJuliet Bakker· per SEC Form D

Co-investorsAPERTURE Venture Partners Essex Woodlands Healthcare Partners Clarus HealthQuest Capital

89bio (NASDAQ: ETNB)89bio.com in

89bio is a clinical-stage biopharmaceutical company developing therapies for patients with liver and cardiometabolic diseases.

Biotech

Co-investorsK2 HealthVentures

Aimmuneaimmune.com

Co-investorsAisling Capital

AirNexisairnexis.com

Co-investorsFrazier Life Sciences OrbiMed

Akebia Therapeuticsakebia.com in 𝕏

Akebia Therapeutics develops FDA-approved drug therapies for the treatment of kidney disease.

BiotechHealthtechMedical DevicesCambridge, US

John P. Butler(President and Chief Executive Officer)

Co-investorsCincyTech

Alentisalentis.ch in

Alentis Therapeutics is a clinical-stage biotech company developing anti-Claudin-1 antibody-drug conjugates (ADCs) and monoclonal antibodies to treat cancer and reverse organ fibrosis.

BiotechHealthtech

Co-investorsAvego BioScience Capital BioMedPartners Catalio Capital Management, LP Frazier Life Sciences Jeito Capital Novo Holdings +3 more

Alpha-9 Oncologya9oncology.com inOct 2024

Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.

BiotechDigital HealthMedical DevicesVancouver, CA

François Bénard(MD)Kuo-Shyan Lin(PhD)David Perrin(PhD)

Co-investorsAndreessen Horowitz Delos Capital General Catalyst Lightspeed Venture Partners Lumira Ventures Nextech Invest +8 more

Amarinamarincorp.com in 𝕏

Amarin Corporation is a cardiovascular health pharmaceutical company developing treatments to prevent cardiovascular disease.

BiotechHealthtechMedical Devices

Co-investorsAvoro Capital Advisors Fountain Healthcare Partners Signet Healthcare Partners Sofinnova Ventures

Amphora MedicalJul 2017

HealthtechMaple Grove, US

Tom Ressemann(Executive Officer, Director)

BoardMichael Liang(Director)Robert Weisskoff(Director)inDan Sachs(Director)

Co-investorsF-Prime Capital Baird Capital HBM Healthcare Investments

Amunixamunix.com

Aptinyxaptinyx.com

BiotechEvanston, US

Joseph R. Moskal(Chief Scientific Officer)Torsten M. Madsen(Chief Marketing Officer)Ashish Khanna(Secretary & Chief Business Officer)Norbert G. Riedel(Chief Executive Officer)

BoardLiam Ratcliffe(Director)Terry P. Gould(Director)

Co-investorsBain Capital Life Sciences Frazier Life Sciences Latterell Venture Partners OUP (Osage University Partners)

Aptus Endosystemsin 𝕏

HealthtechMedia & EntertainmentMedical Devices

Co-investorsUS Venture Partners

Assemblybioassemblybio.com in

Assembly Bio is a biotechnology company developing antiviral therapies for serious viral and liver diseases, including treatments for recurrent genital herpes and chronic hepatitis.

Biotech

Co-investorsAvoro Capital Advisors

Avengebioavengebio.com

Aviceda Therapeutics in

BiotechCambridge, US

Mohamed Genead(Executive Officer, Director)Michael Tolentino(Executive Officer, Director)David Callanan(Executive Officer)Tarek Hassan(Executive Officer)Derek Kunimoto(Executive Officer)

BoardDavid Guyer(Director)

Co-investorsCatalio Capital Management, LP Jeito Capital

Avicedarxavicedarx.com in 𝕏

Avicedar develops glyco-immune checkpoint therapeutics to treat immune-mediated diseases, with an initial focus on Macular Degeneration.

BiotechHealthtech

Co-investorsJeito Capital OrbiMed Digitalis Ventures

Axonicsaxonics.com in

Boston Scientific develops medical devices and technologies used by healthcare professionals to treat patients across a range of conditions.

HealthtechMedical Devices

Raymond Cohenin

Co-investorsAdvent Life Sciences Andera Partners

Baronovabaronova.com

Non-surgical, non-pharmacologic devices to induce weight loss

Co-investorsDelos Capital

Bina health-beautyin 𝕏

BiotechHealthtechMedical Devices

Co-investorsSGH Capital Sunstone Capital

Boltmedboltmed.com in

Bolt Medical develops the Bolt IVL intravascular lithotripsy system, a laser-based balloon catheter platform that fractures arterial calcium using acoustic pressure waves to treat coronary and peripheral artery disease.

HardwareHealthtechMedical DevicesMarlborough, US

Campfieldtxcampfieldtx.com in

cAMPfield is a clinical-stage biopharmaceutical company developing prifemilast, a once-daily oral PDE4B-selective inhibitor for immune-mediated inflammatory diseases, primarily inflammatory bowel disease (ulcerative colitis and Crohn's disease).

BiotechHealthtech

Graham Heap(President, Research and Development)inEzequiel Neimark(Head of Clinical Development)inTaylor Spector(Head of Medical Affairs)inScott Stirn(Head of CMC)in

Co-investorsFrazier Life Sciences

Checkmate Pharmaceuticals

Activating the immune system to recognize and destroy tumor cells.

BiotechCambridge, US

Art Krieg(Executive Officer, Director)Barry Labinger(Executive Officer, Director)Chuck Abdalian(Executive Officer)David Mauro(Executive Officer)Karen Brennan(Executive Officer)Charles Yon(Executive Officer)

Co-investorsF-Prime Capital Sofinnova Ventures Novo Holdings

Checkmatepharmacheckmatepharma.com

Co-investorsSofinnova Ventures

Civitas Therapeuticscivitastherapeutics.comAug 2014

BiotechChelsea, US

RICHARD BATYCKY(Executive Officer)GLENN BATCHELDER(Director)BRYAN STUART(Executive Officer)MARK IWICKI(Executive Officer, Director)MARTIN FREED(Executive Officer)

BoardROB HOPFNER(Director)

Co-investorsCanaan Partners Sofinnova Ventures Bay City Capital OrbiMed RA Capital

Cohere Healthcoherehealth.com inFeb 2024 · $50M

Cohere Health provides a platform aimed at aligning the interests of patients, physicians, and health plans to support care decisions and improve member outcomes.

AI & Machine LearningDigital HealthEnterprise SoftwareHealthtechSaaSBoston, US

Siva Namasivayam(Executive Officer, Director)Robert Shepardson(Executive Officer)Kristen Carucci(Executive Officer)Duncan Reese(Executive Officer)

BoardDavid Barrett(Director)Amir Debourou(Director)

Co-investorsCota Capital Flare Capital Partners Deerfield Management Company Define Ventures Flare Capital Strategies Temasek

Corticacorticacare.com in

Cortica provides in-home, in-clinic, and telehealth neurological therapies for children with autism and developmental differences, integrating neurological, biomedical, behavioral, speech-language, and sensorimotor treatments.

Digital HealthHealthtechMedical DevicesSan Diego, US

Dr. Suzanne Goh(Founder)Neil Hattangadi(Executive Officer, Director)inBriana Elvaiah(Executive Officer)

BoardRyan Drant(Director)inStephen Anastos(Director)Justin Brock(Director)in

Co-investors.406 Ventures AIF APERTURE Venture Partners CVS Health Ventures Echo Health Ventures Optum Ventures +4 more

Crownwheelpartnerscrownwheelpartners.com

CV Therapeuticsgilead.com in 𝕏

Gilead discovers, develops, and delivers innovative therapeutics for people with life-threatening diseases, focusing on virology, oncology, and inflammation across more than 35 countries.

BiotechDigital HealthHealthtechMedical DevicesFoster City, US

Lou Lange(Founder)Michael L. Riordan(Founder)inDaniel O'Dayin

Co-investorsAisling Capital Asset Management Company Frazier Life Sciences Kleiner Perkins Lumira Ventures Menlo Ventures +5 more

CytomXcytomx.com in 𝕏

CytomX is a clinical-stage biopharmaceutical company developing conditionally activated biologic cancer therapies, including antibody-based treatments designed to target tumors while limiting effects on healthy tissue.

BiotechHealthtech

Sean A. McCarthy(Chief Executive Officer and Chairman)Marcia P. Belvin(SVP, Chief Scientific Officer)Dawn Benson(SVP, Quality and Product Manufacturing)Wayne Chu(Chief Medical Officer)Rachael Lester(SVP, Chief Business Officer)Chris Ogden(Chief Financial Officer)

Co-investorsCanaan Partners Pfizer Venture Investments OrbiMed

Dascenadascena.com

Eargoeargo.comDec 2018Defunct

Eargo was a hearing aid company that provided high-quality hearing aids and related care services.

HealthtechMedical DevicesMountain View, US

Raphael Michel(Executive Officer, Director)Christian Gormsen(Executive Officer, Director)William Brownie(Executive Officer)Peter Tuxen Bisgaard(Director)

BoardDavid Wu(Director)inJosh Makower(Director)

Co-investorsBirchmere Ventures Maveron New Enterprise Associates (NEA)Dolby Family Ventures Montage Ventures Red Sea Ventures

Endeavor Biomedicinesendeavorbiomedicines.com in 𝕏

Endeavor BioMedicines is a biopharmaceutical company developing medicines aimed at treating patients with serious, intractable diseases, with the goal of altering disease progression rather than only slowing it.

BiotechSan Diego, US

John Hood(Director, Executive Officer)inWing Cheong Lam(Director)Bernard Davitian(Director)Raghu Saripalli(Executive Officer)Monal Mehta(Director)Miguel de los Rios(Executive Officer)

Co-investorsFidelity Investments

Endogenexendogenex.com in 𝕏

Endogenex is a clinical-stage medical device company developing the pulsENDO system, which applies non-thermal pulsed electric field to reset the body's metabolic signaling and improve function in people with type 2 diabetes.

Digital HealthHealthtechMedical DevicesMinneapolis, US

Stacey Pugh(Leadership (CEO))Chris Sorli, MD, PhD(Chief Medical Officer)inKrissy Wright(Chief Financial Officer)inLian Cunningham, MD, PhD(VP Clinical Affairs)inMelanie Hess(Regulatory Affairs Leadership)inMatt Cambronne(Technical/Engineering Leadership)in

Co-investorsArboretum Ventures Intuitive Ventures Lumira Ventures

Epiriumepirium.com

Epirium Bio develops novel oral therapeutics targeting mitochondrial dysfunction and muscle diseases, particularly muscular dystrophy.

BiotechMedical DevicesSan Diego, US

Pam Taub(M.D., FACC, Founder)Alan Maisel(M.D., Founder)Francisco Villarreal(M.D., Ph.D., Founder)Jonathan Taub(Founder, Chief Executive Officer)Guillermo Ceballos(M.D., Founding Scientist)Russell J. Cox(President and CEO)

Co-investorsBluebird Ventures Broadview Ventures

Esperion Therapeuticsesperion.comJun 2014

BiotechAnn Arbor, US

Antonio M. Gotto, Jr.(Director)Tim M. Mayleben(Executive Officer, Director)Gilbert S. Omenn(Director)Daniel Janney(Director)Dov A. Goldstein(Director)Roger S. Newton(Director)

Co-investorsAisling Capital Alta Partners Arboretum Ventures ARCHIMED Japan Asset Management Company Canaan Partners+2 more

FIRE1fire1foundry.com in 𝕏

FIRE1 develops NORM, an implantable sensor placed in the inferior vena cava to directly measure fluid volume in heart failure patients, paired with a self-management platform to help patients engage with their own care.

Digital HealthHardwareMedical DevicesDublin, IE

Co-investorsAndera Partners Lightstone Ventures New Enterprise Associates (NEA)Vensana Capital

Gcs Webgcs-web.com

Co-investorsKleiner Perkins

Generategenerate.com in

Generate Life Sciences was a reproductive, newborn stem cell, and genetic services company offering products and services to help families grow and protect their families.

BiotechDigital HealthHealthtech

Helicorehelicore.comJan 2025

Helicore Bio develops long-acting antibody-peptide conjugate therapies for obesity and cardiometabolic disease, using proprietary GLP-1R agonist and amylin receptor agonist peptide libraries combined with a GIP ligand-binding antibody backbone.

BiotechHealthtech

Co-investorsOrbiMed Versant Ventures Wellington Management

Helomicshelomics.com inMay 2017acquired by Predictive Oncology

AI & Machine LearningBiotechHealthtechPittsburgh, US

GERALD J. VARDZEL JR.(Executive Officer, Director)DOUGLAS ARMSTRONG(Executive Officer, Director)

BoardROBERT D. KEYSER JR.(Director)RICHARD AULICINO(Director)

Infinant Healthinfinanthealth.com in 𝕏May 2026

Infinant Health develops probiotic products based on B. infantis strains that work with breast milk to support the infant gut microbiome, including its INF108 drug strain aimed at preventing necrotizing enterocolitis (NEC) in premature infants.

BiotechDigital HealthFemTechHealthtechWellness & FitnessSacramento, US

J. Bruce German(Co-founder)David Mills(Co-founder)Carlito Lebrilla(Co-founder)Daniela Barile(Co-founder)Samara Freeman(Co-founder & Director of Intellectual Property and Regulatory Affairs)Michael Johnson(Executive Officer, Director)

Co-investorsAcre Venture Partners Bow Capital Horizons Ventures iSelect Fund Bill & Melinda Gates Foundation Spruce Capital Partners

Inflazomeinflazome.com

Co-investorsFountain Healthcare Partners

Inozyme Pharmainozyme.com

BiotechBoston, US

Axel Bolte(Executive Officer, Director)inReinaldo Diaz(Director)Joseph Schlessinger(Executive Officer, Director)

BoardEdward Mathers(Director)Rob Hopfner(Director)Martin Edwards(Director)

Co-investorsNew Enterprise Associates (NEA)Sanofi Ventures Sofinnova Ventures Pivotal Life Sciences

Intelycareintelycare.com in 𝕏

IntelyCare operates a healthcare talent marketplace that connects nurses with care settings including hospitals, clinics, and other healthcare facilities.

B2B MarketplacesFuture of WorkHealthtechHR TechQuincy, US

Ike Nnah(Executive Officer, Director)David Coppins(Executive Officer, Director)Prince Nnah(Director)

Co-investorsEastward Capital Partners Endeavour Vision Equitage Ventures, L.L.C.Generator Ventures Kaiser Permanente Ventures TRANSFORMATION CAPITAL +1 more

Jazz Pharmaceuticaljazzpharma.com in 𝕏

Jazz Pharmaceuticals is a biopharmaceutical company developing treatments for rare diseases and cancers, with a focus on oncology and biomarker-driven therapies such as those targeting HER2-expressing cancers.

BiotechHealthtech

Co-investorsProspect Venture Partners Rex Health Ventures Solas BioVentures

Lassen Therapeuticslassentherapeutics.com inJan 2024 · $85M

Lassen Therapeutics is a biotechnology company developing therapeutics targeting IL-11, with a pipeline focused on immune and fibrotic diseases.

Biotech

David King(Co-Founder & CSO)Maria Fardis(CEO)Cadmus C. Rich(Chief Medical Officer)Elaine Stracker(General Counsel)

Co-investorsAlta Partners Catalio Capital Management, LP DC Investment Partners Longwood Fund Biotechnology Value Fund Catalio Capital Management +2 more

Lexeotxlexeotx.com in

LEXEO Therapeutics develops gene therapy candidates aimed at genetically mediated cardiovascular diseases and APOE4-associated Alzheimer's disease.

BiotechHealthtech

Co-investorsOrbiMed

Limflowlimflow.com

LimFlow develops a medical device system for the treatment of chronic limb-threatening ischemia.

HealthtechMedical Devices

Co-investorsSofinnova Partners

Locus Bioscienceslocus-bio.com in 𝕏Feb 2024 · $152M

Locus Biosciences develops engineered bacteriophage therapies for treating bacterial infections and conditions in immunology, oncology, and CNS disorders.

AI & Machine LearningBiotechDeep TechHealthtechRaleigh, US

Paul Garofolo(CEO & Co-founder)NICK TAYLOR(Executive Officer)PAUL GAROFOLO(Executive Officer, Director)Nick Conley(Vice President of Technology (Co-founder of EpiBiome, acquired by Locus))

BoardGEOFFREY GLASS(Director)DAVID JOHNSTON(Director)

Co-investorsArtis Ventures Abstract Ventures Hemisphere Ventures LLC Domain Associates Starlight Ventures

Lumena Pharmaceuticalsin 𝕏acquired by Shire

Acquired by Shire in 2014 (now part of Takeda).

BiotechMedical Devices

Co-investorsFrazier Life Sciences Oberland Capital RiverVest Venture Partners

Mtemmtem.com

Molecular Templates, Inc. was a clinical-stage biopharmaceutical company formerly based in Austin, TX.

BiotechAustin, US

Co-investorsSofinnova Ventures Solasta Ventures

Murjmurj.com in 𝕏

Murj provides a software platform for cardiac clinics, tailoring its solution to each clinic's specific workflows and challenges.

Digital HealthHealthtechMedical DevicesSaaSSanta Cruz, US

Patrick Beaulieu(Founder)inTodd Butka(Founder)

BoardMark Bartell(Director)Reed Gaither(Co-founder)

Co-investorsTrue Ventures

Nabrivanabriva.com

Co-investorsAisling Capital EcoR1 Capital

Nalunalumed.com in 𝕏

Nalu Medical develops a non-integrated neurostimulation system that uses electrical impulses to interrupt pain signals for patients with intractable chronic nerve pain.

HardwareHealthtechMedical DevicesCarlsbad, US

Earl Fender(President & CEO)Lee Hartley(Executive Officer)Allen Meacham(Executive Officer)Bick Sellers(Executive Officer)Thomas A. West(Executive Officer, Director)Jeffrey Swiecki(Executive Officer)

Co-investorsAPERTURE Venture Partners B Capital Group B4 Capital Decheng Capital Endeavour Vision Runway Growth Capital +1 more

Neurana Pharmaceuticals

Developing a novel treatment for acute muscle spasms.

BiotechSan Diego, US

Kathleen D. Scott(Chief Financial Officer, Secretary and Treasurer)Judy Caron(Chief Operating Officer)David F. Hale(Chairman of the Board of Directors, Acting President and CEO)Brian Dorsey(Director)Daniel Becker(Director)Joshua Richardson(Director)

Co-investorsSofinnova Ventures H.I.G. HealthBridge Partners

nocdtreatmyocd.com in 𝕏

NOCD provides specialized treatment for obsessive-compulsive disorder through live video sessions with OCD-trained therapists and 24/7 in-app support between sessions, using exposure and response prevention (ERP) therapy.

Digital HealthHealthtechMental HealthChicago, US

LARRY TRUSKY(Executive Officer)STEPHEN M. SMITH(Executive Officer, Director)Stephen Smith(Cofounder)

BoardGLEN TULLMAN(Director)in

Co-investors7wire Ventures Chicago Ventures Corewell Health Ventures F-Prime Capital Kaiser Permanente Ventures Meridian Street Capital +2 more

NxStage Medicalnxstage.com in 𝕏acquired by Fresenius Medical Care

NxStage, part of Fresenius Medical Care, makes portable hemodialysis systems that let kidney patients perform home hemodialysis and peritoneal dialysis, including solo and nocturnal treatment.

Digital HealthHardwareHealthtechMedical DevicesLawrence, US

Co-investorsCross Creek Advisors

On Belay Health Solutionsonbelayhealthsolutions.com in

On Belay provides tools, resources, and guidance to support primary care teams in transitioning to value-based care models and strengthening their practices across the United States.

Enterprise SoftwareHealthtechSaaS

Co-investors.406 Ventures Maverick Ventures

Opna Bioopnabio.com

Co-investorsMenlo Ventures

Orbus Therapeuticsorbustherapeutics.com

Orbus Therapeutics is a clinical-stage biopharmaceutical company developing eflornithine (DFMO), an oral ODC inhibitor, as a cancer therapy.

BiotechHealthtechAptos, US

Jason Levin(Founder, Director and Chief Executive Officer)Jason D. Levin(Executive Officer, Director)Robert M. Myers(Executive Officer, Director)

BoardMichael Wasserman(Director)Patrick Enright(Director)Elisha (Terry) Gould(Director)

Co-investorsH.I.G. Capital H.I.G. HealthBridge Partners Agent Capital

OrsoBioorsobio.com in 𝕏Nov 2023 · $60M

BiotechMenlo Park, US

Mani Subramanian(Executive Officer, Director)Gangadhara Ganapati(Executive Officer, Director)

BoardMatthew Young(Director)inSrinivas Akkaraju(Director)Cory Freedland(Director)Edward Fleming(Director)

Co-investorsSamsara BioCapital Ascenta Capital

Pentec Health Celebrates 35th Anniversaryin 𝕏

This page is a distribution, marketing, and reseller partner directory for PRWeb, an online press release distribution service.

Marketing TechMedia & EntertainmentSaaS

Co-investorsAdvance Venture Partners Angel Physicians Fund Avestria Ventures Aviv Venture Capital BIGR Ventures Blue Venture Funds+15 more

Polares Medicalpolaresmedical.com in

Polares Medical is a medical device company developing a device for treating mitral valve regurgitation.

HealthtechMedical DevicesPalo Alto, US

Alex Khairkhahan(Founder)in

Co-investorsDecheng Capital Earlybird Venture Capital Endeavour Vision IDO Investments

Poseida Therapeuticsposeida.com in

Poseida Therapeutics develops cell therapy candidates and related platform technologies for healthcare applications.

BiotechHealthtechSan Diego, US

Eric Ostertag(Executive Officer, Director)Mark Gergen(Executive Officer, Director)

BoardAdrian Howd(Director)David Hirsch(Director)

Co-investorsAisling Capital Rapha Capital Management, LLC Vivo Capital

Practice Fusionpracticefusion.com in 𝕏

Practice Fusion provides a cloud-based electronic health record (EHR) platform with integrated medical billing services and e-prescribing for independent medical practices.

Digital HealthHealthtechSaaSSan Francisco, US

Ryan Howard(Executive Officer, Director)Beth Seidenberg(Director)Michael Harden(Director)

BoardMark Goines(Director)Cora Tellez(Director)

Co-investorsBand of Angels Canvas Ventures

Quanta Therapeuticsquantatx.comMay 2023 · $50M

Quanta is a biotech company developing orally bioavailable, CNS-penetrant small-molecule KRAS inhibitors targeting RAS-driven cancers such as pancreatic, colorectal, lung, and endometrial cancers.

BiotechDeep TechHealthtechSouth San Francisco, US

Cameron Pitt(Executive Officer, Director)Ying Huang(Director)Derek Metzger(Executive Officer)

BoardMaha Katabi(Director)Perry Nisen(Executive Officer, Director)Maria Fardis(Director)

Co-investorsSofinnova Ventures Vida Ventures Biotechnology Value Fund Frazier Life Sciences

Rapidmicrobiorapidmicrobio.com

Rivus Pharmaceuticals, Inc.rivuspharma.com in 𝕏

Rivus develops oral medicines for cardiometabolic health using its proprietary development platform.

BiotechDigital HealthCharlottesville, US

Allen Cunningham(Executive Officer, Director)Nancy Hargreaves(Executive Officer)Jayson Dallas(Executive Officer, Director)Shaharyar Khan(Executive Officer, Director)

BoardFrancesco De Rubertis(Director)inDerek DiRocco(Director)in

Co-investorsMedicxi RA Capital

Sierra Oncologysierraoncology.com in 𝕏

A biopharmaceutical company that discovers, develops, and delivers medicines and vaccines, with research and development across respiratory, immunology and inflammation, oncology, HIV, and infectious diseases.

BiotechHealthtechMedical DevicesSan Francisco, US

Co-investorsCapital Midwest Fund Frazier Life Sciences RA Capital Vivo Capital Oxford Finance LLC

Solta Medicalsolta.com in

Solta Medical develops and sells a portfolio of aesthetic skin treatment devices, including the Thermage line, used by medical and cosmetic practices to address common skin concerns such as skin tightening and contouring.

HardwareMedical DevicesWellness & Fitness

Co-investorsNew Enterprise Associates (NEA)

Somatussomatus.com in

Somatus provides value-based, integrated kidney care and a congestive heart failure management solution for patients, providers, and health plan partners.

Digital HealthHealthtechMclean, US

Ikenna Okezie(Executive Officer, Director)Alexander Houlday(Executive Officer)Stacey Queen-Pyndell(Executive Officer)

BoardAnna Haghgooie(Director)Anthony Welters(Director)

Co-investorsFlare Capital Partners Optum Ventures HealthQuest Capital Blue Venture Funds Defy Partners RA Capital +4 more

Talaristxtalaristx.com

Co-investorsAisling Capital

Theseus Pharmaceuticalstheseusrx.comJan 2021

BiotechCambridge, US

William C. Shakespeare(Director)

BoardIain Dukes(Executive Officer, Director)inMichael Rome(Director)Carl Gordon(Director)in

Co-investorsForesite Capital Nextech Invest OrbiMed

Thumbnail for Constellation Pharmaceuticalsin 𝕏

BiotechHealthtech

Co-investorsClal Biotechnology Industries ExSight Ventures Tachyon Ventures The Column Group

Tourmaline Biotourmalinebio.com

Co-investorsAvoro Capital Advisors Scion Life Sciences TCG Crossover Vivo Capital

Tricidatricida.com

BiotechSouth San Francisco, US

Gerrit Klaerner(Executive Officer, Director)Melissa Miksch(Executive Officer)

BoardSandra Coufal(Director)David Bonita(Director)inKlaus Veitinger(Director)inRobert Alpern(Director)

Co-investorsAvoro Capital Advisors OrbiMed

Ventaris Surgicalventarissurgical.com inJan 2026

BiotechSan Carlos, US

Surag Mantri(Executive Officer, Director)

BoardJustin Klein(Director)inMatthew Sprinkel(Director)Amir Abolfathi(Director)Varun Gupta(Director)

Co-investorsBoutique Venture Partners Neotribe Ventures Vensana Capital

Veratxveratx.com in 𝕏

Vera Therapeutics develops medicines targeting autoimmune-driven kidney diseases, with a focus on reducing the need for dialysis or transplant.

BiotechDigital HealthMedical Devices

Co-investorsKleiner Perkins Sofinnova Ventures

Viridian Therapeuticsviridiantherapeutics.com in 𝕏

Viridian Therapeutics develops treatments for thyroid eye disease, a rare autoimmune condition affecting the eyes and orbit.

BiotechDigital HealthMedical DevicesWaltham, US

Jonathan Violin(Executive Officer, Director)

BoardPeter Harwin(Director)Tomas Kiselak(Director)

Co-investorsBroadview Ventures MRL Ventures Fund

Welbe Healthwelbehealth.com in 𝕏

WelbeHealth operates a Program of All-Inclusive Care for the Elderly (PACE) that provides integrated medical and social services to seniors, including primary care, dental, vision, hearing, in-home care, transportation, and social activities.

Digital HealthHealthtechWellness & FitnessCalifornia, US

Si France, MD(Founder)inADAM GROFF(MANAGER OF ISSUER)CLANCY SI FRANCE(MANAGER AND CHIEF EXECUTIVE OFFICER OF ISSUER)MICHAEL ZUBKOFF(MANAGER OF ISSUER)JONATHAN LIM(MANAGER OF ISSUER)

BoardLIAM DONOHUE(MANAGER OF ISSUER)

Co-investors.406 Ventures General Atlantic

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Exits · 18

IPOs and acquisitions across the tracked portfolio

VeradermicsNYSE: MANECeribellNASDAQ: CBLLAeonbiopharmaNYSE: AEONBioAge LabsNASDAQ: BIOABoston ScientificNYSE: BSXCG OncologyNASDAQ: CGONCollegium PharmaceuticalNASDAQ: COLLCorcept TherapeuticsNASDAQ: CORTCytomX TherapeuticsNASDAQ: CTMXKALA BIONASDAQ: KALAKestra Medical TechnologiesNASDAQ: KMTSMicroTransponderNASDAQ: MOBIRxsightNASDAQ: RXSTVaxcyteNASDAQ: PCVXZenas BiopharmaNASDAQ: ZBIOHelomicsacq. by Predictive OncologyLumena Pharmaceuticalsacq. by ShireNxStage Medicalacq. by Fresenius Medical Care

Portfolio news

latest coverage across their companies

CG Oncology stock hits all-time high of 79.5 USD By Investing.com

CG Oncology · investing.com · Aug 19, 2026

Cohere Health Recognized in 2026 Gartner® Hype Cycle™ for U.S. Healthcare Payers for Fifth Consecutive Year - AOL

Cohere Health · aol.com · Aug 18, 2026

JPMorgan Chase & Co. Cuts CytomX Therapeutics (NASDAQ:CTMX) Price Target to $11.00 - Ticker Report

CytomX Therapeutics · tickerreport.com · Aug 16, 2026

KALA BIO Announces Brief Delay in Quarterly Filing - TipRanks.com

KALA BIO · tipranks.com · Aug 14, 2026

Collegium Pharmaceutical Initiates $50 Million Accelerated Share Buyback with Jefferies LLC

Collegium Pharmaceutical · kalkinemedia.com · Aug 13, 2026

RxSight’s Long-Term Lens Study: What Ongoing Results Could Mean For RXST Investors - TipRanks.com

Rxsight · tipranks.com · Aug 12, 2026

CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update - BioSpace

CytomX · biospace.com · Aug 7, 2026

Veradermics Tumbles as Lock-Up Expiry Spooks Investors - TipRanks.com

Veradermics · tipranks.com · Aug 3, 2026

Fund performance · per public LP disclosures

as of Jun 2025

Fund	Vintage	Committed	Net IRR	TVPI	DPI
Longitude Venture Partners IIILPs: Los Angeles City Employees' Retirement System, Maryland State Retirement and Pension System	2016	—	16.8%	1.68x	0.96x

Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).

Public market activity · per SEC filings

what is this? ⓘ

2 insider ownership filings (Forms 3/4/5)

at Veradermics, Inc (MANE)

From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.

Frequently asked questions

How many investments has Longitude Capital made?: Longitude Capital has 92 tracked investments, 4 of which have exited via acquisition or IPO, including 4 dated in the last 24 months.
What stage does Longitude Capital invest at?: Longitude Capital invests at the Series A, Series B, Series C, Growth, Late Stage stages.
What is Longitude Capital's typical check size?: Longitude Capital typically writes checks of $10M – $30M.
What sectors does Longitude Capital focus on?: Longitude Capital focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
Where is Longitude Capital located?: Longitude Capital is headquartered in Menlo Park, US.
Does Longitude Capital lead rounds?: Yes, Longitude Capital leads investment rounds.
Who does Longitude Capital co-invest with?: Longitude Capital most often shares deals with RA Capital, Frazier Life Sciences, New Enterprise Associates (NEA), among 179 tracked co-investors.

Co-investors · 6

Menlo Ventures

Menlo Ventures is a venture capital firm that invests in transformative, early-stage AI companies across every layer of the modern AI stack, from applications and middleware to data infrastructure and foundation models.

Both backed · 2

CV TherapeuticsOpna Bio

$1M – $20M

Vensana Capital

Vensana Capital is a venture capital and growth equity investment firm focused on partnering with entrepreneurs building breakthrough medical technology innovations to transform healthcare.

Both backed · 2

FIRE1 Ventaris Surgical

Pivotal Life Sciences

Pivotal Life Sciences is an investment platform focused on funding innovative companies developing therapeutic products and technologies aimed at major unmet medical needs.

Both backed · 1

Inozyme Pharma

Longwood Fund

Longwood Fund is a venture capital firm that creates and invests in novel healthcare companies developing new treatments for patients, drawing on its partners' company-building and operating experience.

Both backed · 1

Lassen Therapeutics

GE Ventures

Bain Capital Venture

Bain Capital is a global private investment firm operating across private equity, growth and venture capital, credit, capital solutions, and real assets, with offices in North America, Europe, and Asia-Pacific. The firm invests across industries and business life cycles, from seed-stage venture investments through buyouts, and integrates sustainability commitments into its portfolio governance.

Firms observed investing alongside Longitude Capital, from public investor directories. Shared companies are the overlap with Longitude Capital's recorded portfolio.

Similar investors

GV (Google Ventures)

GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.

$250K – $50M

Khosla Ventures

Khosla Ventures is a venture capital firm that invests in early-stage companies focused on technology, mobile, and clean energy sectors, including biotechnology applications. The firm provides capital and strategic support to entrepreneurs developing breakthrough technologies across multiple markets.

$5K – $50M

LSP (Life Sciences Partners)

EQT Life Sciences, formerly LSP (Life Sciences Partners), is one of Europe's largest and most experienced life sciences investors, backing companies developing therapeutics, medical devices, diagnostics and healthtech.

$10.8M – $64.8M

Novo Holdings

Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.

$1.1M – $54M

Lumira Ventures

Lumira Ventures is a North American life sciences venture capital firm that partners with mission-driven entrepreneurs to build companies developing and commercializing healthcare products for patients.

$1M – $10M